Your browser doesn't support javascript.
loading
A high-throughput microfluidic mechanoporation platform to enable intracellular delivery of cyclic peptides in cell-based assays.
Kasper, Stephen H; Otten, Stephanie; Squadroni, Brian; Orr-Terry, Cionna; Kuang, Yi; Mussallem, Lily; Ge, Lan; Yan, Lin; Kannan, Srinivasaraghavan; Verma, Chandra S; Brown, Christopher J; Johannes, Charles W; Lane, David P; Chandramohan, Arun; Partridge, Anthony W; Roberts, Lee R; Josien, Hubert; Therien, Alex G; Hett, Erik C; Howell, Bonnie J; Peier, Andrea; Ai, Xi; Cassaday, Jason.
Affiliation
  • Kasper SH; Merck & Co., Inc. Cambridge Massachusetts USA.
  • Otten S; Merck & Co., Inc. Cambridge Massachusetts USA.
  • Squadroni B; Merck & Co., Inc. West Point Pennsylvania USA.
  • Orr-Terry C; Merck & Co., Inc. Cambridge Massachusetts USA.
  • Kuang Y; Merck & Co., Inc. Cambridge Massachusetts USA.
  • Mussallem L; Merck & Co., Inc. West Point Pennsylvania USA.
  • Ge L; Merck & Co., Inc. Kenilworth New Jersey USA.
  • Yan L; Merck & Co., Inc. Kenilworth New Jersey USA.
  • Kannan S; Agency for Science, Technology and Research (A*STAR) Singapore Singapore.
  • Verma CS; Agency for Science, Technology and Research (A*STAR) Singapore Singapore.
  • Brown CJ; Agency for Science, Technology and Research (A*STAR) Singapore Singapore.
  • Johannes CW; Agency for Science, Technology and Research (A*STAR) Singapore Singapore.
  • Lane DP; Agency for Science, Technology and Research (A*STAR) Singapore Singapore.
  • Chandramohan A; MSD International Singapore Singapore.
  • Partridge AW; MSD International Singapore Singapore.
  • Roberts LR; Merck & Co., Inc. Cambridge Massachusetts USA.
  • Josien H; Merck & Co., Inc. Kenilworth New Jersey USA.
  • Therien AG; Merck & Co., Inc. Cambridge Massachusetts USA.
  • Hett EC; Merck & Co., Inc. Cambridge Massachusetts USA.
  • Howell BJ; Merck & Co., Inc. West Point Pennsylvania USA.
  • Peier A; Merck & Co., Inc. Kenilworth New Jersey USA.
  • Ai X; Merck & Co., Inc. Kenilworth New Jersey USA.
  • Cassaday J; Merck & Co., Inc. West Point Pennsylvania USA.
Bioeng Transl Med ; 8(5): e10542, 2023 Sep.
Article in En | MEDLINE | ID: mdl-37693049
Cyclic peptides are poised to target historically difficult to drug intracellular protein-protein interactions, however, their general cell impermeability poses a challenge for characterizing function. Recent advances in microfluidics have enabled permeabilization of the cytoplasmic membrane by physical cell deformation (i.e., mechanoporation), resulting in intracellular delivery of impermeable macromolecules in vector- and electrophoretic-free approaches. However, the number of payloads (e.g., peptides) and/or concentrations delivered via microfluidic mechanoporation is limited by having to pre-mix cells and payloads, a manually intensive process. In this work, we show that cells are momentarily permeable (t 1/2 = 1.1-2.8 min) after microfluidic vortex shedding (µVS) and that lower molecular weight macromolecules can be cytosolically delivered upon immediate exposure after cells are processed/permeabilized. To increase the ability to screen peptides, we built a system, dispensing-microfluidic vortex shedding (DµVS), that integrates a µVS chip with inline microplate-based dispensing. To do so, we synced an electronic pressure regulator, flow sensor, on/off dispense valve, and an x-y motion platform in a software-driven feedback loop. Using this system, we were able to deliver low microliter-scale volumes of transiently mechanoporated cells to hundreds of wells on microtiter plates in just several minutes (e.g., 96-well plate filled in <2.5 min). We validated the delivery of an impermeable peptide directed at MDM2, a negative regulator of the tumor suppressor p53, using a click chemistry- and NanoBRET-based cell permeability assay in 96-well format, with robust delivery across the full plate. Furthermore, we demonstrated that DµVS could be used to identify functional, low micromolar, cellular activity of otherwise cell-inactive MDM2-binding peptides using a p53 reporter cell assay in 96- and 384-well format. Overall, DµVS can be combined with downstream cell assays to investigate intracellular target engagement in a high-throughput manner, both for improving structure-activity relationship efforts and for early proof-of-biology of non-optimized peptide (or potentially other macromolecular) tools.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Bioeng Transl Med Year: 2023 Document type: Article Country of publication: Estados Unidos

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Bioeng Transl Med Year: 2023 Document type: Article Country of publication: Estados Unidos